Every Form 4 that BridgeBio Oncology Therapeutics, Inc (BBOT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BBOT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BBOT filings page.
BridgeBio Oncology Therapeutics, Inc. principal accounting officer Marc Cobo reported a routine tax-related share disposition. On the vesting of restricted stock units, the company withheld 125 shares of Common Stock to cover his tax obligations, rather than selling them in the open market. Following this withholding, Cobo directly holds 5,306 shares of Common Stock.
BridgeBio Oncology Therapeutics, Inc. reported a routine insider equity event for COO & Principal Financial Officer Elmelech Idan. The company withheld 343 shares of Common Stock at $7.80 per share to cover his tax obligations tied to vesting restricted stock units. This was a tax-withholding disposition, not an open-market trade, and reflects how part of his equity award was used to pay taxes. After this withholding, Idan directly holds 14,495 shares of the company’s common stock.
BridgeBio Oncology Therapeutics, Inc. Chief Medical & Development Officer Ben Yong had 1,047 shares of common stock withheld on July 1, 2026 to cover tax obligations tied to vesting restricted stock units. This was an automatic tax-withholding disposition at $7.80 per share, not an open-market trade. After this transaction, Yong directly owned 44,576 shares of BridgeBio Oncology common stock.
BridgeBio Oncology Therapeutics, Inc. reported that President and CEO Pedro Beltran had 1,047 shares of Common Stock withheld by the company at $7.80 per share to cover tax obligations from vesting restricted stock units. After this withholding, he directly holds 44,576 shares of Common Stock. This was a tax-withholding disposition, not an open-market sale.
BridgeBio Oncology Therapeutics, Inc. director and 10% owner Bihua Chen reported indirect ownership changes tied to a restructuring among investment vehicles associated with Helix Holdings II LLC, the Sponsor. The filing shows a pro rata distribution of 4,528,186 common shares from the Sponsor to its members for no consideration.
According to the footnotes, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare Fund V, LP, and Cormorant Global Healthcare Master Fund, LP each received shares in this pro rata distribution, and Cormorant Private Healthcare Fund IV, LP is also managed by the same investment manager. Post-transaction indirect holdings include 1,905,046 shares via Fund IV and 6,083,221 shares via the Master Fund. The transactions are classified as "other" (code J), reflect internal allocations with no open-market buying or selling, and include disclaimers that Ms. Chen and the funds only beneficially own securities to the extent of their pecuniary interests.
BridgeBio Oncology Therapeutics director Praveen P. Tipirneni received a stock option grant for 31,675 shares of Common Stock. The option has an exercise price of $7.73 per share and expires on June 15, 2036. It vests in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders, subject to his continued service. Following this grant, he holds options for 31,675 shares directly, with no open-market buying or selling reported in this filing.
BridgeBio Oncology Therapeutics director Frank McCormick received a new stock option grant. He was awarded options for 31,675 shares of common stock at an exercise price of $7.73 per share. These options were granted at no upfront cost and are held as a direct ownership position.
The options vest in full on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting, as long as he continues serving the company through that date. Following this grant, his reported derivative holdings from this award total 31,675 underlying shares.
BridgeBio Oncology Therapeutics director Peter F. Lebowitz received a grant of stock options covering 7,289 shares of common stock. The options have an exercise price of $7.73 per share and expire on June 15, 2036. According to the terms, they vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders, provided he continues serving the company through that vesting date. After this grant, Lebowitz holds 7,289 stock options directly.
BridgeBio Oncology Therapeutics director Raymond J. Kelleher received a new stock option grant covering 31,675 shares of Common Stock. The options have an exercise price of $7.73 per share and expire on June 15, 2036, giving him the right to buy shares at that price in the future.
The award vests in full on the earlier of the first anniversary of the June 16, 2026 grant date or the next Annual Meeting of Stockholders, as long as he continues serving the company through that date. After this grant, he holds 31,675 stock options directly.
BridgeBio Oncology Therapeutics director and 10% owner Chen Bihua received a grant of stock options for 31,675 shares of common stock. The options have an exercise price of $7.73 per share and expire on June 15, 2036.
The options vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders that follows the grant date, provided Chen continues to serve the company through that vesting date. After this grant, Chen holds 31,675 derivative securities directly.
BridgeBio Oncology Therapeutics, Inc. director Jake Bauer reported a compensation-related stock option grant covering 31,675 shares of common stock at an exercise price of $7.73 per share. The options vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders, and expire on June 15, 2036. Following this grant, Bauer holds stock options for 31,675 underlying shares directly.
BridgeBio Oncology Therapeutics director Neil Kumar received a stock option grant for 31,675 shares of common stock at an exercise price of $7.73 per share. The option vests in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continued service, and expires in 2036. Following this grant, he holds 31,675 derivative securities directly.
BridgeBio Oncology Therapeutics COO and Principal Financial Officer Elmelech Idan received a grant of stock options for 758,222 shares of Common Stock. The options have an exercise price of 7.6600 per share and expire on May 9, 2036. Vesting occurs in 48 substantially equal monthly installments beginning on April 20, 2026, contingent on continued service.
BridgeBio Oncology Therapeutics reported that President and CEO Pedro Beltran received a grant of stock options covering 1,103,837 shares of common stock. The options have an exercise price of $7.66 per share and were awarded at no cost to him.
These options expire on May 9, 2036 and vest in substantially equal monthly installments, with 1/48 of the total vesting on each monthly anniversary of April 20, 2026, contingent on his continued service. Following this grant, he holds options for 1,103,837 shares directly.
BridgeBio Oncology Therapeutics, Inc. Chief Med & Dev Officer Ben Yong reported a routine tax-related share disposition. On April 1, 2026, 1,047 shares of Common Stock were withheld by the company at $9.03 per share to cover his tax obligations upon vesting of restricted stock units. After this withholding, Yong directly holds 45,623 shares of the company’s Common Stock, indicating he retains the vast majority of his equity position and that the transaction was not an open-market sale.
BridgeBio Oncology Therapeutics, Inc. President and CEO Pedro Beltran had 1,047 shares of Common Stock withheld at $9.03 per share to cover tax obligations from the vesting of restricted stock units.
After this tax-withholding disposition, he directly holds 45,623 shares of the company’s Common Stock. This is a routine, non–open-market event tied to equity compensation rather than an active sale in the market.
BridgeBio Oncology Therapeutics, Inc. former officer Uneek Mehra reported a small share disposition tied to taxes, not an open-market trade. On the vesting of restricted stock units, the company withheld 524 shares of Common Stock at $9.03 per share to cover tax withholding obligations. After this tax-withholding transaction, Mehra directly holds 22,806 shares of BridgeBio Oncology common stock.
BridgeBio Oncology Therapeutics, Inc. director Peter F. Lebowitz received a grant of stock options covering 63,350 shares of common stock. The options have an exercise price of $8.72 per share and expire on March 23, 2036.
According to the vesting terms, 1/36th of the options vest in substantially equal monthly installments on each monthly anniversary of March 24, 2026, so long as he continues to provide service to the company. Following this grant, he holds 63,350 derivative securities directly.
BridgeBio Oncology Therapeutics, Inc. reported that Chief Financial Officer Uneek Mehra received new equity awards. On March 10, 2026, he was granted stock options covering 105,000 shares of common stock at an exercise price of $10.19 per share, expiring on March 9, 2036.
The option vests in substantially equal monthly installments, with 1/48 of the shares vesting each month from January 1, 2026, contingent on continued service. He also received 23,330 restricted stock units, each representing one share of common stock, vesting in 16 equal quarterly installments over four years from January 1, 2026, and settling in shares upon vesting.
BridgeBio Oncology Therapeutics, Inc. Chief Scientific Officer Pedro Beltran received new equity awards as part of his compensation. He was granted an option for 210,000 shares of common stock at an exercise price of 10.19 per share, vesting in substantially equal monthly installments from January 1, 2026.
He also received 46,670 restricted stock units, each representing one share of common stock. These RSUs vest in 16 equal quarterly installments over four years from January 1, 2026, and are settled in shares upon vesting, subject to his continued service.
BridgeBio Oncology Therapeutics, Inc. reported that Chief Medical & Development Officer Ben Yong received new equity awards on March 10, 2026. He was granted a stock option for 210,000 shares of Common Stock at an exercise price of $10.19 per share, expiring in 2036.
He also received 46,670 restricted stock units (RSUs), each representing one share of Common Stock. The RSUs vest in 16 equal quarterly installments over four years from January 1, 2026, and the option vests in 48 substantially equal monthly installments from the same date, in each case contingent on continued service.
BridgeBio Oncology Therapeutics, Inc. reported an update to its Chief Executive Officer and director’s stock option grant. On December 10, 2025, the company rescinded 1,114,400 stock options from an option grant originally dated October 2, 2025, as an exempt disposition to the issuer under Rule 16b-3.
After this change, 500,000 stock options from the original grant remain outstanding, each with an exercise price of $12.44 and an expiration date of October 1, 2035. The options vest in 48 substantially equal monthly installments beginning on the monthly anniversary of October 2, 2025, as long as the reporting person continues to provide service to the company on each vesting date.
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported a Form 4 disclosing that Eli M. Wallace, who serves as Chief Executive Officer and a director, was granted a stock option on 10/02/2025. The option covers 1,614,400 shares of common stock with an exercise price of $12.44 per share and an expiration date of 10/01/2035. The option becomes exercisable in equal monthly installments equal to 1/48th of the total award, beginning on 10/02/2025, subject to continued service. The reporting person is shown as the direct holder of the option and the Form 4 was signed by an attorney-in-fact on 10/06/2025.